Swine influenza, also known as swine flu, is a highly contagious respiratory disease caused by Type-A influenza viruses that infect the respiratory tracts of pigs. Swine influenza viruses are mostly found in pigs. However, occasionally, they have also been found to be spread among humans who have direct contact with infected pigs. The swine influenza disease spreads in humans usually through two routes: pig-to-human transmission and human-to-human transmission. Pig-to-human transmission occurs mostly in farms where humans are in direct contact with infected pigs, and hence, these people usually take precaution of using face masks. Human-to-human transmission occurs when humans carrying influenza virus cough or sneeze, and spread the virus. It is then inhaled by other humans. Fever, body ache, headache, runny nose, fatigue, and vomiting are a few symptoms of the swine influenza disease. Based on viral surface antigens, Type-A influenza viruses are classified as: hemagglutinin (H) and neuraminidase (N). There exist four types of Type-A influenza viruses and they are as follows:
The respiratory infection in humans is caused by H1N1 influenza virus. For instance, in 1988, swine flu infection in Wisconsin resulted in multiple cases of swine flu in humans.
Based on antiviral drug therapeutics, the swine influenza market can be segmented into three major segments:
- Tamiflu: Also referred to as oseltamivir phosphate, Tamilflu is available in the form of capsules. These are used to prevent or lessen the spread of Type-A influenza virus.
- Relenza: Also known as Zanamivir, Relenza is used to treat Type-A and Type-B influenza virus infection by blocking the action of neuraminidase. It is an enzyme produced by the influenza virus, which spreads from already infected cells to healthy cells.
- Peramivir: This drug has been developed by BioCryst Pharmaceuticals for the treatment of influenza virus. In 2009 pandemic of H1N1 influenza, Peramivir was authorized for emergency use in the treatment of infected patients. This drug has been approved in Japan and South Korea.
In terms of geography, the global swine influenza market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global swine influenza market, followed by China. Major driving factors for the swine influenza market in these regions are high prevalence of infection and development of several novel drugs that have helped in the treatment of swine influenza. Both developed and developing countries are vulnerable to the threat caused by swine influenza in humans. Asia Pacific is one of the most lucrative markets for swine influenza, owing to presence of developing economies in the region. Key factors likely to augment the swine influenza market in Asia Pacific in the next few years are weak immune systems of people in the region and increasing rate of past history infections. For instance, the 2009 swine flu pandemic affected around 394,133 people in Asia with 2,137 confirmed deaths. Moreover, easy market penetration and increasing government aid are estimated to fuel the swine influenza market in the region in the near future.
Some of the key players operating in the global swine influenza market are GlaxoSmithKline, Novartis, AstraZeneca PLC, Vical Incorporated, Baxter International, Inc., Celltrion, Inc., Lipoxen PLC, Novavax, Inc., and Medicago, Inc.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.